A Rare Case of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Obscured by Alkalosis.

Autor:	Fernandez Felix DA; Medicine, St. Barnabas Hospital (SBH) Health System, Bronx, USA.; Clinical Medicine, Sophie Davis School of Medicine, City University of New York, Bronx, USA., Madrigal Loria G; Medicine, St. Barnabas Hospital (SBH) Health System, Bronx, USA.; Clinical Medicine, Sophie Davis School of Medicine, City University of New York, Bronx, USA., Sharma S; Medicine, St. Barnabas Hospital (SBH) Health System, Bronx, USA.; Clinical Medicine, Sophie Davis School of Medicine, City University of New York, Bronx, USA., Sharma S; Medicine, St. Barnabas Hospital (SBH) Health System, Bronx, USA.; Clinical Medicine, Sophie Davis School of Medicine, City University of New York, Bronx, USA., Arias Morales CE; Medicine, St. Barnabas Hospital (SBH) Health System, Bronx, USA.; Clinical Medicine, Sophie Davis School of Medicine, City University of New York, Bronx, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Jun 10; Vol. 14 (6), pp. e25818. Date of Electronic Publication: 2022 Jun 10 (Print Publication: 2022).
DOI:	10.7759/cureus.25818
Abstrakt:	Empagliflozin-induced euglycemic diabetic ketoacidosis is a life-threatening metabolic complication of diabetes mellitus characterized by metabolic acidosis, ketonemia, and relatively normal serum glucose levels. We present a rare case of empagliflozin-induced diabetic ketoacidosis obscured by alkalosis. This case report aims to create awareness among clinicians about this entity and consider this diagnosis in their differential, especially in patients taking sodium-glucose co-transporter (SGLT-2) inhibitors who present to the hospital with unspecific symptoms that may not suggest DKA. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Fernandez Felix et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu